Stratos Wealth Partners LTD. lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 29.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,671 shares of the medical equipment provider’s stock after selling 7,512 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Zimmer Biomet Holdings were worth $2,069,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after acquiring an additional 33 shares during the last quarter. BB&T Investment Services Inc. bought a new position in shares of Zimmer Biomet Holdings in the second quarter worth about $144,000. Sandy Spring Bank lifted its holdings in shares of Zimmer Biomet Holdings by 5.4% in the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 66 shares during the last quarter. Finally, Grove Bank & Trust lifted its holdings in shares of Zimmer Biomet Holdings by 346.1% in the second quarter. Grove Bank & Trust now owns 1,316 shares of the medical equipment provider’s stock worth $169,000 after acquiring an additional 1,021 shares during the last quarter. 85.44% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/16/stratos-wealth-partners-ltd-reduces-stake-in-zimmer-biomet-holdings-inc-zbh.html.

Several research firms have recently issued reports on ZBH. BidaskClub downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Cantor Fitzgerald set a $137.00 price objective on Zimmer Biomet Holdings and gave the company a “hold” rating in a research note on Thursday, July 27th. Canaccord Genuity downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and lowered their price objective for the company from $141.00 to $135.00 in a research note on Friday, July 28th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $137.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Friday, July 28th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $133.71.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down $1.13 during mid-day trading on Thursday, hitting $111.08. 1,149,900 shares of the stock traded hands, compared to its average volume of 1,364,914. The firm has a market cap of $22,719.51, a P/E ratio of 13.90, a price-to-earnings-growth ratio of 1.74 and a beta of 1.17. Zimmer Biomet Holdings, Inc. has a one year low of $98.20 and a one year high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same period last year, the business earned $1.79 EPS. equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current year.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.